SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CUBIST PHARMACEUTICALS (CBST) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (244)4/7/2011 3:32:27 PM
From: idos  Respond to of 252
 
On CBST valuation - think good news has just been priced in but not sure pipeline has. If CXA-201 phase II data are as good as I hope, then I see one good reason to hold on.



To: tuck who wrote (244)4/7/2011 4:19:33 PM
From: rkrw  Read Replies (1) | Respond to of 252
 
Flagyl is first line right now.



To: tuck who wrote (244)4/8/2011 9:30:00 AM
From: kenhott  Read Replies (2) | Respond to of 252
 
Cubicin is a nice little drug. Might get a pullback in price because the story is not clear. Don't know if mgt wants to sell but there would be buyers at the right price. CBST has like $140m in annual SG&A.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News